|
22 May 2019 |
Social |
Fibomyalgia patients who undergo Knee replacements have significantly more complications (OR 1.55), revisions (OR 1.5), mechanical loosening (OR 1.34) & infection (OR 1.33). MDs and FM pts should be made aware of increased postoperative risks. https://t.co/muFQoco9zg |
|
|
21 May 2019 |
Social |
US Supreme court has rejected lawsuits against Merck & Fosamax over rare atypical femoral Fx and has directed the lower court to reconsider ruling allowing lawsuits against despite the FDA denying Mercks attempt to update the label about fracture risk https://t.co/xvJlDntuuK |
|
|
17 May 2019 |
Social |
Review of Factors Contributing to Functional Outcomes after Knee replacement includes: Weight, pain & smoking (increase post-op complications), pain, infection (2% w/in 1st 90days), post-operative range of motion and (severity of) the OTHER knee. https://t.co/mKe8EQnk8q |
|
|
06 May 2019 |
News |
CDC: One in Four US Adults have Arthritis |
|
|
02 May 2019 |
Social |
Osteoarticular involvement with sarcoidosis is uncommon (<13%); in the hands shows a honeycomb/latticework trabecular pattern in metacarpals https://t.co/bE4VgWaEzN |
|
|
25 Apr 2019 |
News |
More Studies Needed to Optimize the Use of Osteoporosis Drugs |
|
|
24 Apr 2019 |
ACR Video |
RheumNow Live Preview with Dr. Kenneth Mathis |
|
|
23 Apr 2019 |
News |
NIH Workshop on Unmet Needs in Osteoporosis |
|
|
22 Apr 2019 |
Social |
RCT of 63 knee OA pts - given PBO or 40 g/d freeze-dried blueberry powder x 4 mos. Significant improvement in WOMAC total, Pain scoresand ADL scores in the blueberry group, but no change in TNFα,IL-1β, IL-6, IL-10, IL-13, MMP3, MMP-13, MCP-1 levels. https://t.co/wHzCJDOuiJ |
|
|
19 Apr 2019 |
Social |
Phase 3 study tanezumab (anti-NGF) 2.5 mg or 5 mgin knee or hip OA find that 5 mg met 2/3 of 3 primary endpoints at 16wks; but the lower dose failed to be superior to NSAIDs in this 1 yr study. Safety outcomes where less favorable w/ tanezumab. https://t.co/l4Qffdn1nl |
|
|
17 Apr 2019 |
Social |
Lateral wedge insoles are often used medial knee OA. Study of 63 preselected pts shows a significant pain reduction (vs neutral soles) but mean difference was 0.7 on 0–10 scale; thus benefitting only a minority of pts https://t.co/7SK7Cl1Uft |
|
|
16 Apr 2019 |
News |
Intraarticular Trans-Capsaicin Effective in Knee OA |
|
|
16 Apr 2019 |
News |
Smoking Not Protective Against Knee OA |
|
|
16 Apr 2019 |
Social |
The price of new osteoporosis drug Evenity (romosuzumab; sclerostin inhibitor) is $1,825/mo. or $21,900/Yr; Just FDA approved for post-menopausal OP at high risk for Fx . Amgen estimates Evenity to be 34-74% lower than Tymlos & Forteo. https://t.co/lYHyukTRPw |
|
|
15 Apr 2019 |
Social |
Metanalysis of 6 studies suggests that metformin use was inversely associated with the risk of fracture (RR 0.82; 95% CI 0.72, 0.93). https://t.co/ZTmHnpMvS6 |
|
|
10 Apr 2019 |
News |
FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis |
|
|
09 Apr 2019 |
Social |
Data from the Osteoarthritis Initiative (n 4369) shows that fluctuating or persistent Knee pain over 1 yr had an increased risk of cartilage volume loss and structural progression over 4 years (OR 1.62, 95% CI 1.04–2.54) https://t.co/Inf4WsQ4Lz |
|
|
27 Mar 2019 |
News |
Guidelines for Osteoporosis Management in Postmenopausal Women |
|
|
23 Mar 2019 |
Social |
Dr Phil Conaghan on the similarity between OA and PsA #RNL2019 https://t.co/za9YDAWilE |
|
|
21 Mar 2019 |
Social |
A review of OP Guidelines, published in Osteoporosis International, shows only 27 of the 70 guidelines patient Beliefs, Values or Perceptions. https://t.co/zGoX2aaxdP |
|
